Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Real-time Estimate Cboe BZX 01:33:09 2024-03-28 pm EDT 5-day change 1st Jan Change
11.8 USD -0.21% Intraday chart for Viatris Inc. -1.67% +9.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Viatris Inc. - Special Call
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod MT
Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc.. CI
Global markets live: 3M Company, Bayer, Apple, Boeing, Nvidia... Our Logo
Are good times already over? Our Logo
Viatris Says Mapi Pharma Receives FDA Complete Response Letter on Potential Multiple Sclerosis Drug MT
US FDA declines to approve Viatris's injection for multiple sclerosis RE
Viatris Insider Sold Shares Worth $1,005,609, According to a Recent SEC Filing MT
Atomo Diagnostics Wins Order to Supply AU$970,000 Worth of HIV Self-Tests MT
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. CI
Sector Update: Health Care Stocks Decline Premarket Wednesday MT
Viatris Inc. Provides Revenue Guidance for the Full Year and Second Of Fiscal 2024 CI
Transcript : Viatris Inc., 2023 Earnings Call, Feb 28, 2024
Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024 CI
Viatris Swings to Q4 Loss as Revenue Falls; 2024 Guidance Issued MT
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia, Europe Down MT
(VTRS) VIATRIS Forecasts Fiscal Year 2024 EPS Range $2.70 - $2.85 MT
Earnings Flash (VTRS) VIATRIS Reports Q4 Revenue $3.84B, vs. Street Est of $3.88B MT
Caution Undercuts Wall Street Pre-Bell; Asia, Europe Off MT
Viatris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Viatris Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod MT
MORNING BID AMERICAS-US tracking 3%+ growth; Apple downshifts, Kiwi surprise RE
Viatris Inc. announces an Increase in Equity Buyback. CI
Chart Viatris Inc.
More charts
Viatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company's ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
11.83 USD
Average target price
12.4 USD
Spread / Average Target
+4.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Viatris Inc. - Nasdaq
  4. News Viatris Inc.
  5. Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit